Medtronic plc’s recent launch of the Viaverte basivertebral nerve ablation system and completion of the acquisition of SPR Therapeutics Inc. broadens its chronic pain offering and strengthens its ability to treat patients across the pain care continuum.

Total med-tech financing through the first half (H1) of 2026 reached $12.66 billion, down from 2025’s $17.56 billion but in line with 2024’s $13.94 billion over the same period.

Dassault Systèmes agreed to buy Arisglobal for up to $2 billion as it strengthens its position in the life sciences sector, advancing its ambition to create a unified AI intelligence platform for the industry where datasets are currently fragmented. The deal brings together Arisglobal’s AI-powered safety and regulatory intelligence platform with Dassault’s own position in scientific modeling and simulation, to create what the company calls the industry’s first AI platform that unifies real-world evidence with virtual evidence.

The U.S. FDA granted Johnson & Johnson de novo authorization for its Ottava robotic surgical system, which can now be marketed for multiple surgeries, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy and others.

Science Corp. launched its Prima retinal implant in Europe after receiving CE mark approval under the Medical Device Regulation, a significant milestone for the brain-computer interface (BCI) field. However, unlike most BCIs, which decode neural activity to translate thoughts into actions, Prima writes visual information into the nervous system to restore vision.

While the pace of executive orders (EOs) coming out of the White House continues to decline, the impact of new EOs on U.S. health agencies, life sciences industries and the practice of medicine remains just as disconcerting as a year ago.

In a rapid-fire voting session, the U.S. House suspended the rules July 20 to pass, by voice vote, a slate of bipartisan health bills ranging from reducing animal testing in drug development to clarifying Medicare coverage of wheelchairs.

An increase in the level of M&A activity and some sizeable financing rounds are encouraging signs for the med-tech investment environment, said Joey Mason, life sciences venture partner at Claret Capital Partners. He pointed to Medtronic plc’s acquisition of SPR Therapeutics Inc., and Neurent Medical Ltd.’s large fundraise earlier in the year, as evidence of the improving sentiment.

AMT Medical BV reported positive one-year data from a study looking at its ELANA device, a sutureless coronary bypass technology designed to simplify one of the most technically demanding steps in coronary artery bypass grafting, and potentially expand use of the minimally invasive procedures.

On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the company for $16.25 per share, which amounts to an enterprise value of $1.5 billion net of Tempus’ existing ownership interest.